Juliana Campos, PhD

Juliana Campos, PhD

Juliana Campos (MSc, PhD) is a freelance writer with a strong scientific background in biomedicine, cellular and molecular biology, and biochemistry, and a keen interest in science communication.

All articles by Juliana Campos, PhD

subcutaneous injection

Long-Term Prophylaxis With C1-INH Could Help Reduce the Burden of HAE

Reducing the burden of hereditary angioedema (HAE) could be possible with adequate dosing and frequency of administration of C1 inhibitor (C1-INH), even for patients with highly symptomatic HAE activity, according to data from randomized controlled trials evaluating the administration of C1-INH replacement therapy as long-term prophylaxis in patients with HAE. Up to 83% of patients…

DNA variants

Case Report: Novel LIPA Variant With Preserved Enzyme Activity Discovered

A novel variant of uncertain significance in the LIPA gene was found in 2 pairs of siblings presenting with clinical and biochemical findings suggestive of lysosomal acid lipase deficiency (LAL-D). However, since the patients had residual levels of lysosomal acid lipase (LAL) activity, a definite diagnosis of LAL-D could not be established. “When confronted with…

DNA genetics

Study Finds Causal Associations Between IPF and Several Comorbidities

A new study published in Chest found causal associations between idiopathic pulmonary fibrosis (IPF) and certain comorbidities, using a bidirectional Mendelian randomization (MR) approach. According to the results, genetic liability to gastroesophageal reflux disease (GERD), venous thromboembolism (VTE), and hypothyroidism were associated with increased risk of IPF. Conversely, genetic liability to chronic obstructive pulmonary disease…

DNA mutation

Trial of Experimental Gene Therapy for Cardiomyopathy in FA Currently Recruiting

A phase 1/2, open-label, dose-ascending, multicenter clinical trial set to evaluate LX2006 in patients with Friedreich ataxia (FA) and evidence of cardiomyopathy is currently recruiting. The trial, initiated on August 24, 2022, aims to enroll 10 patients with a confirmed genetic diagnosis of FA and an onset before 25 years of age. Additional inclusion criteria…

Clinical trials

Two Phase 1b Clinical Trials Underway to Evaluate MASP-3 Inhibitor in PNH

Two phase 1b clinical trials are underway to evaluate OMS906—Omeros Corporation’s inhibitor of mannose-binding lectin-associated serine protease 3 (MASP-3), the key activator of the alternative complement pathway—in patients with paroxysmal nocturnal hemoglobinuria (PNH). One of the trials is designed to evaluate OMS906 in patients with PNH who are treatment-naïve, while the other trial includes patients…

Case Report

Trial Will Evaluate Iodine-124 Evuzumitide in Patients With Systemic Amyloidosis

Recruiting is underway for a single-center prospective clinical trial evaluating iodine-124 evuzumitide (124I-evuzumitide) in patients with systemic amyloidosis, of which hereditary transthyretin amyloidosis (hATTR) is a form. The trial aims to “identify and characterize the distribution and uptake of 124I-evuzumitide in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)” and correlate 124I-evuzumitide uptake with the structure and…

woman inhaling medication

Positive Topline Results Announced for Multiphage Therapeutic in Cystic Fibrosis

Armata Pharmaceuticals has announced positive topline results from its phase 1b/2a SWARM-P.a. trial assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of AP-PA02 for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF). “We are pleased to present topline data for our lead multiphage candidate, AP-PA02, which was evaluated in cystic…

blood tranfusion

Rapid Clinical Deterioration Occurs in Patient With LAL-D After ERT Interruption

A team from the Universidade Federal de Sao Paulo in Brazil reported the case of a patient with lysosomal acid lipase deficiency (LAL-D) who experienced severe malabsorption after interrupting enzyme replacement therapy (ERT). “This case serves as an alert that when ERT is interrupted, there is a rapid clinical deterioration,” the team wrote in an…

serum vials

Study Finds Predictor of End-Stage Kidney Disease in AAV With Glomerulonephritis

The global glomerulitis score could be a predictor of end-stage kidney disease (ESKD) in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with glomerulonephritis (AAV-GN), according to a preprint posted in Research Square. “This study is the first to show that global glomerulitis independently predicted the progression to ESKD in Korean patients with AAV-GN. Therefore,…

Mouse in exercise wheel

Novel Bioactive Fumarate Extends the Lifespan of an FA Mouse Model

Researchers developed a novel monomethyl fumarate prodrug with an improved pharmacokinetic profile that enhanced cardiac function and expanded the lifespan of a Friedreich ataxia (FA) mouse model, according to an abstract presented at the 67th Biophysical Society Annual Meeting in San Diego, California. The novel bioactive fumarate, IMF, but not dimethyl fumarate (Tecfidera®), extended the…

Next post in FA News Briefs